[ABBV] AbbVie: Q3 2026 Earnings Preview, Can Skyrizi Hold Its $21.7 Billion Pace?

AbbVie discovers, manufactures and sells prescription medicines and aesthetic products across immunology, neuroscience, oncology and aesthetics, and its earnings calendar shows a results call on 2026-10-30[1] covering the third quarter of 2026, ending September 30, 2026. In the latest disclosed quarter, the second quarter of 2026, AbbVie reported revenue of $16.990 billion, up 10.2% (up 9.5% operationally), immunology revenue of $8.786 billion, up 14.6% operationally, adjusted diluted EPS of $3.65, up 22.9%, and GAAP EPS of $2.03[2]. On its second-quarter call, management guided third-quarter revenue to approximately $17.2 billion and adjusted EPS to $3.84-$3.88[3], and the company reaffirmed that range on September 3 when it closed the Apogee acquisition; the range excludes any acquired in-process R&D (IPR&D) and milestone expense that may be incurred in the third quarter[4]. As of September 29, the revenue consensus compiled by Drillr from 11 analysts stood at $17.312 billion, slightly above company guidance, and the EPS consensus from 12 analysts stood at $3.86, equal to the midpoint of guidance[5]; the earnings calendar records an EPS estimate of $3.82, and the two datasets are updated on different schedules[1].

Three things matter most in this AbbVie Q3 2026 earnings preview. The first is whether Skyrizi can hold its roughly $21.7 billion full-year revenue assumption: it delivered $9.988 billion in the first half[6], so it needs about $5.86 billion per quarter in the second half, roughly $350 million more than its second-quarter $5.505 billion, and Skyrizi and Rinvoq together already account for about 47% of company revenue[7], which makes this figure the direct test of whether immunology can keep offsetting Humira's decline. The second is whether aesthetics can stop falling: the segment declined 0.9% operationally in the second quarter, with U.S. Botox Cosmetic down 2.4% and Juvederm down 6.6%, and because this is the company's only consumer-paid business, the third-quarter direction can separate a temporary dip from lost share. The third is whether the first quarter after consolidating Apogee can turn revenue growth into adjusted EPS of $3.84-$3.88: the company has already raised full-year adjusted net interest guidance by $200 million to about $2.9 billion, and its full-year adjusted operating margin guidance of "approaching 47%" sits below the second quarter's 48.3%[3], so the third quarter will be the first to carry both the added R&D and the interest on acquisition borrowing.

Company Background and Business Structure

AbbVie was spun off from Abbott in 2013, is headquartered in North Chicago, Illinois, trades on the New York Stock Exchange and is led by chairman and chief executive officer Robert A. Michael. Its core therapeutic areas are immunology, neuroscience and oncology, and the 2020 acquisition of Allergan added aesthetics (Botox Cosmetic and Juvederm fillers) and eye care. Its largest historical product, Humira, lost U.S. exclusivity in 2023, and its 2025 revenue fell 49% under direct biosimilar competition[8]; since then the company has relied on two newer immunology drugs, Skyrizi and Rinvoq, and on neuroscience products such as Vraylar, Botox Therapeutic and its migraine medicines to carry growth.

Since the start of 2026, two events have changed the company's financial structure. The first is a voluntary agreement with the U.S. government: AbbVie will offer low prices in Medicaid and expand direct-to-patient sales, and it pledged $100 billion in U.S. research and development and capital investment over the next decade, in exchange for a three-year exemption from tariffs and future price mandates[9]. The second is the acquisition of Apogee, a developer of long-acting antibodies for atopic dermatitis and asthma, at a total equity value of about $10.9 billion; its core assets are zumilokibart (APG777), a half-life extended antibody targeting IL-13, and APG273, a long-acting combination targeting IL-13 and TSLP[10]. The deal closed on September 3 at $135.11 per share in cash, and AbbVie said it will reduce adjusted EPS by $0.14 in 2026 and by about $0.46 in 2027, with accretion beginning in 2032[11].

AbbVie reports a single operating segment but discloses revenue by therapeutic area and product. Of second-quarter 2026 revenue of $16.990 billion, immunology contributed $8.786 billion, or 51.7%, including Skyrizi at $5.505 billion, Rinvoq at $2.525 billion and Humira at $756 million; neuroscience contributed $3.228 billion, or 19.0%, including Vraylar at $1.071 billion, Botox Therapeutic at $1.042 billion and Vyalev at $256 million; oncology contributed $1.650 billion, or 9.7%, including Venclexta at $771 million, Imbruvica at $532 million and Elahere at $211 million; and aesthetics contributed $1.282 billion, or 7.5%, including Botox Cosmetic at $728 million and Juvederm at $245 million[7]. The remaining revenue comes from mature products such as Creon, Mavyret, Linzess and eye care. U.S. revenue in the quarter was $12.861 billion, about 76% of the total, so U.S. pricing and reimbursement conditions determine the direction of most of the revenue.

Revenue passes through wholesalers and payers before it reaches patients. In 2025, three wholesalers, McKesson, Cardinal Health and Cencora, handled substantially all of AbbVie's U.S. prescription drug sales, although no single wholesaler accounted for more than 43% of U.S. gross revenue[12]; revenue is recognized at net price after rebates to PBMs, Medicare and Medicaid, so rebate negotiations and government price-setting change revenue directly. Aesthetic products are sold directly to clinics and paid for by consumers. On costs, the second-quarter adjusted gross margin was 84.7%, adjusted SG&A was 21.0% of revenue, adjusted R&D was 13.6%, and acquired IPR&D and milestones expense added another 1.7%[13], the last being an unpredictable one-time item.

Financial History and Current Position

The annual record shows that AbbVie has moved past the revenue trough that followed Humira's loss of exclusivity. From 2023 through 2025, revenue was $54.318 billion, $56.334 billion and $61.160 billion, with 8.6% growth in 2025 and U.S. revenue of $46.603 billion[14]. Over the same period, Humira fell from $14.404 billion to $4.540 billion, while Skyrizi rose from $7.763 billion to $17.562 billion and Rinvoq rose from $3.969 billion to $8.304 billion[15], so the gains from the two newer drugs now exceed Humira's losses.

GAAP profit in 2025 sat far below operating performance because of several large non-cash or one-time charges. AbbVie reported 2025 operating earnings of $15.1 billion and diluted EPS of only $2.36, after $7.4 billion of intangible asset amortization and a $6.5 billion change in the fair value of contingent consideration[16]; the contingent consideration change mainly reflected higher estimated Skyrizi sales, and a further $5.016 billion of IPR&D came from deals including Capstan and Gilgamesh[17]. On a GAAP basis, the 2025 gross margin was 70%, SG&A was 23% of revenue and R&D was 15%[18]. On cash, 2025 operating cash flow was $19.030 billion and capital expenditure was about $1.2 billion[19], which shows that most of the income-statement charges do not consume cash.

In the first half of 2026, revenue growth accelerated while the gap between GAAP and adjusted results stayed wide. Revenue was $15.002 billion in the first quarter and $16.990 billion in the second, compared with $15.423 billion in the second quarter of 2025; second-quarter GAAP operating earnings were $6.432 billion[20], the GAAP operating margin was 37.9% against an adjusted 48.3%, and GAAP EPS was $2.03 against adjusted EPS of $3.65, which already includes a $0.17 unfavorable IPR&D impact[13]. The change in contingent consideration fair value still added a $1.5 billion charge in the second quarter and $3.9 billion in the first half[21], one of the main reasons GAAP and adjusted EPS differ by about $1.60.

The balance sheet is re-levering because of the Apogee deal, while full-year guidance moved slightly after the second quarter. First-half operating cash flow was $7.265 billion, above $6.788 billion a year earlier, capital expenditure was $587 million, and AbbVie paid $6.2 billion in dividends and $1.1 billion in buybacks[22]. At the end of June, cash was $6.569 billion, the current portion of long-term debt was $8.341 billion and long-term debt was $62.481 billion, for total debt of about $70.8 billion[23]; on August 18 the company also completed a $10 billion notes offering with maturities from 2028 to 2066[24]. AbbVie changed its 2026 adjusted EPS guidance from $13.91-$14.11 to $13.87-$14.07, a range that includes a $0.58 unfavorable impact from first-half IPR&D but excludes any IPR&D incurred after the second quarter[25]; it raised full-year revenue guidance by $300 million to about $67.6 billion[3].

Operating Model

Revenue equals the patients on therapy or units shipped for each product multiplied by net price after rebates. About 76% of revenue comes from the United States and ships almost entirely through the three major wholesalers, and net price depends on rebates to PBMs, Medicare and Medicaid and on government price-setting. The growth engine is the newer immunology drugs: Skyrizi and Rinvoq generated $8.030 billion together in the second quarter, up about 24%, and they have to offset Humira's continuing decline ($756 million in the quarter, down 36.1% operationally); the second engine is neuroscience ($3.228 billion, up 19.8%); aesthetics ($1.282 billion) reflects discretionary consumer demand; and in oncology ($1.650 billion, down 2.4%), Imbruvica is weighed down by government pricing and competition while Venclexta and Elahere are still growing[7]. The company says its business has no significant seasonality, but wholesaler inventory changes and buying patterns can cause quarterly swings[12], which means a single quarter needs to be read against the half-year trend.

Adjusted operating profit depends on revenue scale and a few expense ratios, while GAAP profit is also moved by two accounting items. In the second quarter, the adjusted gross margin was 84.7%, and after SG&A of 21.0% of revenue, R&D of 13.6% and acquired IPR&D of 1.7%, the adjusted operating margin was 48.3%[13]; full-year guidance calls for a margin approaching 47%, with adjusted R&D of about $9.8 billion and adjusted net interest of about $2.9 billion[3]. The GAAP line also absorbs roughly $7 billion a year of intangible amortization and a contingent consideration remeasurement that rises as expected Skyrizi sales rise, so the better Skyrizi performs, the higher the GAAP charge[17]. Revenue growth reaches adjusted profit first through gross margin and SG&A leverage, and after Apogee is consolidated, its R&D and borrowing costs will offset part of that leverage in the second half.

Cash flow broadly tracks adjusted profit, capital spending is light, and the cash goes mainly to dividends, external deals and debt service. Operating cash flow equals adjusted profit minus taxes, working capital changes and cash payments such as contingent consideration and litigation; 2025 operating cash flow was $19.030 billion with capital expenditure of about $1.2 billion[19]. The roughly $10.9 billion cash price for Apogee was financed through the $10 billion notes issued in August[24] and a $10 billion 364-day term loan facility that was undrawn when the 10-Q was filed[26]. Management targets a net leverage ratio of 2x within two to three years of closing while keeping the financial flexibility to pursue more deals[3], which means cash flow in the next few years has to cover dividends, deleveraging and new transactions at the same time.

Industry and Competitive Position

AbbVie is one of the world's largest pharmaceutical companies by revenue, and its competitive position is currently strongest in immunology. Its immunology products compete with IL-23, IL-17 and JAK inhibitors and with biosimilars[27], against drugs from companies such as Johnson & Johnson, Eli Lilly, Novartis and Amgen. Management says Skyrizi leads psoriasis market share in more than 30 countries, captures four times as many new and switching U.S. patients as any competing biologic or oral treatment, and led U.S. new patient starts in inflammatory bowel disease[28]; under settlement agreements, no generic Rinvoq is expected in the United States before April 2037[29]. Because Skyrizi's patent life runs longer, AbbVie's immunology revenue faces no obvious exclusivity expiry before the 2030s.

Competition in neuroscience and aesthetics is more fragmented, but AbbVie also holds leading positions in its niches there. Vraylar leads in schizophrenia and bipolar disorder and Botox Therapeutic leads in chronic migraine, yet several companies market neurotoxins positioned against Botox, and oncology faces targeted therapies such as BTK inhibitors, ADCs and cell therapies[27]. In aesthetics, AbbVie is responding by widening its portfolio: the short-acting neurotoxin Boey is approved in the EU and Canada[30], but its U.S. application received an FDA complete response letter in the first quarter over manufacturing questions, with no safety or efficacy issues raised[31].

U.S. drug pricing policy is a structural pressure shared across the industry and especially concrete for AbbVie. Imbruvica has been subject to Medicare Part D government-set prices since 2026, and Vraylar and Linzess will be from 2027[32], while Botox was selected in January 2026 as one of 15 medicines subject to government-set prices in Medicare Parts B and D beginning in 2028[9]. The available disclosures do not give patient counts, net prices, rebates or new-patient share figures, so any share comparison between Skyrizi and its competitors rests on revenue and management's qualitative statements, which is the main limit on judging competitive position.

Core Debates

As Humira keeps shrinking, can Skyrizi and Rinvoq keep pace with the roughly $21.7 billion full-year Skyrizi assumption and hold immunology growth in double digits in the third quarter?

Immunology sets the direction of AbbVie's overall growth because Skyrizi and Rinvoq already make up about 47% of company revenue. Second-quarter immunology revenue was $8.786 billion, 51.7% of company revenue, up 14.6% operationally; within it, Skyrizi generated $5.505 billion, Rinvoq $2.525 billion and Humira $756 million, with Humira still shrinking at a 36.1% rate[7]. Humira fell from $14.404 billion in 2023 to $4.540 billion in 2025[15], so continued growth depends on the two newer drugs' share of new patients, and the first full quarter after new competitor launches will show whether that share is loosening.

The case for continuation rests on the latest quarter and on management's statements. In the second quarter, Skyrizi grew 24.0% and Rinvoq 23.7% operationally[7], and after the quarter the company raised its full-year Skyrizi revenue assumption by $100 million to about $21.7 billion[3]. Management says Skyrizi captures four times as many new and switching U.S. patients as any competitor[28], and that its new patient acquisition rate has improved since March 2026, with most of the new competitor's share gains coming from older oral therapies[33]. Generic Rinvoq cannot enter the U.S. before April 2037 at the earliest[29], so immunology faces no new exclusivity expiry within the visible horizon.

The case against is that growth is slowing while the second-half requirement is rising. Skyrizi growth has fallen from about 50% in 2025[8] to 24% in the second quarter, and a higher base will keep pulling year-over-year growth down; given first-half sales of $9.988 billion[6], Skyrizi needs about $5.86 billion per quarter in the second half, roughly $350 million more than in the second quarter. An alternative explanation is that part of the second-quarter beat came from quarterly swings in U.S. channel inventory or rebates rather than new-patient share, in which case third-quarter sequential growth would slow noticeably. Financially, new and switching patients choosing Skyrizi and Rinvoq add patients on therapy and lift the two drugs' revenue, while biosimilars keep eroding Humira, and the difference between the two sets the growth rate of immunology and of total revenue.

The third-quarter report offers several concrete tests of this debate. The most direct is whether Skyrizi's third-quarter revenue reaches at least about $5.8 billion, followed by whether Rinvoq's operational growth holds near 22% and whether Humira's decline stays in the -30% to -40% range; readers should also watch whether management changes its description of the impact from new competitors such as an oral IL-23 drug, and the FDA decision on subcutaneous Skyrizi induction for Crohn's disease, which management anticipated in fall 2026[28]. If Skyrizi comes in below $5.6 billion and the full-year assumption is cut, or new competitors begin taking Skyrizi's new patients, the current view that the two drugs can fully replace Humira would weaken.

Neuroscience grew nearly 20% in the second quarter; can it keep pace with the roughly $12.7 billion full-year assumption in the third quarter without leaning on Vraylar pricing?

Neuroscience is AbbVie's second-largest franchise and its fastest-growing revenue source outside Skyrizi and Rinvoq. Second-quarter neuroscience revenue was $3.228 billion, up 19.8% operationally, including Vraylar at $1.071 billion, Botox Therapeutic at $1.042 billion, Ubrelvy and Qulipta at $742 million combined and Vyalev at $256 million[2]. The franchise depends on several mid-sized products growing at once, and Vraylar becomes subject to Medicare government-set prices from 2027[32], so share gains in the second half of 2026 determine how large this revenue is before that price pressure arrives.

The case for continuation is that growth is broad and the company has just raised its full-year assumption. In the second quarter, Vraylar grew about 19%, Vyalev grew more than 27% sequentially, and Botox Therapeutic, Ubrelvy and Qulipta all delivered double-digit growth[34]; the company raised its full-year neuroscience revenue assumption by $100 million to about $12.7 billion[3] and said Vyalev is on track to reach blockbuster status in 2026[28]. In 2025, Vraylar generated $3.621 billion and Botox Therapeutic $3.769 billion[35], so these two products already provide a large revenue base.

The case against points to pricing contribution and slowing growth in some products. The 10-Q attributes part of Vraylar's growth to favorable pricing without disclosing how large that contribution is, and Ubrelvy's growth slowed from 26.5% in the first half to 16.0% in the second quarter[36]. An alternative explanation is that part of the second-quarter acceleration came from pricing and channel factors and that growth will fall back to around 15% in the second half, which could still meet the full-year assumption but would leave little room for another raise. The transmission path runs from higher prescribing share among psychiatrists and neurologists, including Vraylar, preventive and acute migraine treatment and subcutaneous Parkinson's infusion, to more patients on therapy and higher neuroscience revenue; the new drug tavapadon, if approved in the third quarter, would start slowly because it misses Medicare formulary cycles[37].

The third-quarter test for this debate is fairly clear. Based on the roughly $12.7 billion full-year assumption and first-half revenue of $6.103 billion[6], third-quarter neuroscience revenue needs to be at least about $3.3 billion; readers should also watch whether Vraylar growth stays above 15% and how the company describes the pricing contribution, whether Ubrelvy and Qulipta grow sequentially on a combined basis, whether Vyalev grows sequentially to about $290 million or more, and whether tavapadon is approved in the third quarter. If neuroscience revenue falls below $3.15 billion and the full-year assumption is cut, or Vyalev declines sequentially, the view that several products are ramping together would weaken.

Aesthetics slipped back into a year-over-year decline in the second quarter; can consumer-paid Botox Cosmetic and Juvederm stabilize in the third quarter?

Aesthetics is small, but it is AbbVie's only business driven by consumer payment rather than insurance reimbursement. Second-quarter aesthetics revenue was $1.282 billion, about 7.5% of total revenue[7]; it carries a higher gross margin and is the clearest end-demand signal outside Skyrizi and Rinvoq. In 2025, U.S. Botox Cosmetic revenue fell 10.5% and global Juvederm fell 15.3% at constant currency[38], making the business a visible drag on company growth.

The evidence for stabilization is limited but real. First-half aesthetics revenue grew 1.9% operationally, which implies first-quarter growth of about 5.1%[6], and international Botox Cosmetic grew 12.1% operationally in the second quarter[7]. The company won EU and Canadian approval for Boey, a short-acting neurotoxin, and U.S. approval for a new Skinvive indication for neck lines[30], and management believes Boey will expand the overall aesthetic toxin market[28].

The evidence against is concentrated in the U.S. market and in fillers. Aesthetics declined 0.9% operationally in the second quarter, with U.S. Botox Cosmetic down 2.4% and Juvederm down 6.6%[7]; the 10-Q attributes Juvederm's decline to lower consumer demand and unfavorable pricing, and notes that part of first-half Botox Cosmetic growth came from favorable pricing tied to prior-year changes in the U.S. customer loyalty program[39], while management acknowledges ongoing headwinds in dermal filler markets[37]. An alternative explanation is that the U.S. problem is share loss to competitors rather than weak total demand, in which case AbbVie's aesthetics revenue would struggle to recover even if consumer conditions improve. In financial terms, consumer-paid visits and clinic restocking set Botox Cosmetic and Juvederm volumes, loyalty program discounts set net price, and together they drive aesthetics revenue and the weight of high-margin products in the revenue mix.

Four measures will show whether the third quarter stabilizes aesthetics. The first is whether third-quarter operational growth returns above 0%, the second is whether U.S. Botox Cosmetic turns positive, the third is whether Juvederm's decline narrows to within -5%, and the last is whether management attributes the weakness to market demand or to share. If aesthetics declines year over year for two consecutive quarters by more than 3%, or U.S. Botox Cosmetic's decline widens, the view that the weakness is only a temporary dip would weaken.

In the first quarter after closing Apogee, can AbbVie reach its $3.84-$3.88 adjusted EPS guidance while carrying higher R&D and interest costs?

The third quarter is the first in which AbbVie carries revenue growth, Apogee R&D and new interest at the same time, and it will decide how reliable the $13.87-$14.07 full-year guidance is. The company's adjusted margins are high, with a second-quarter adjusted operating margin of 48.3%[13], but the roughly $10.9 billion all-cash Apogee acquisition will reduce adjusted EPS by $0.14 in 2026 and by about $0.46 in 2027[11] and adds interest expense through new debt.

The case for meeting guidance rests on the second-quarter beat and two reaffirmations. Second-quarter adjusted EPS was $3.65[2], 6 cents above the midpoint of the company's earlier $3.57-$3.61 guidance[40], and revenue came in about $300 million above the company's expectations[28]; after the quarter the company raised full-year revenue guidance to about $67.6 billion[3] and, when the acquisition closed on September 3, reaffirmed both its third-quarter and full-year EPS guidance[4].

The case against is that operating leverage is weakening and one expense cannot be forecast. Full-year adjusted operating margin guidance of approaching 47% is below the second quarter's 48.3%, which implies a higher expense ratio in the second half; full-year adjusted net interest guidance was raised by $200 million to about $2.9 billion[3], implying about $790 million per quarter in the second half versus $679 million in the second quarter[20]. IPR&D is excluded from guidance and would directly lower EPS in any quarter it occurs[25], and the $10 billion of notes issued in August carry rates between 4.5% and 6.1%[24]. An alternative explanation is that EPS delivery relies mainly on revenue beats while operating leverage fades; the transmission runs from revenue growth through gross margin and SG&A leverage to a higher adjusted operating margin, while Apogee's added R&D and acquisition borrowing costs pull adjusted EPS down.

Testing this debate in the third-quarter report requires stripping out IPR&D first. The key checks are whether adjusted EPS excluding third-quarter IPR&D is at least $3.86, whether revenue is at least about $17.2 billion, whether the adjusted operating margin is at least 47%, whether net interest stays within about $790 million, and how large third-quarter IPR&D is. If EPS excluding IPR&D falls below $3.84, or full-year EPS guidance is cut after excluding new IPR&D, the view that revenue growth can absorb Apogee's costs would weaken.

Risks and Falsifiers

U.S. drug pricing policy is the most certain external risk and the one that hits revenue most directly. Imbruvica has been subject to Medicare government-set prices since 2026, and its second-quarter revenue was $532 million, down 29.4%[7], a decline the company attributes to IRA pricing and competition[37]; Vraylar, with 2025 revenue of $3.621 billion, becomes subject to government-set prices from 2027, and Botox Therapeutic, with 2025 revenue of $3.769 billion[35], follows as Botox enters government price-setting from 2028[9]. The voluntary agreement with the U.S. government trades Medicaid low prices and direct sales for a three-year exemption from tariffs and future price mandates, which reduces near-term uncertainty but does not change the Medicare price-setting schedule already in place. If Imbruvica's decline stops widening in the third quarter and the company discloses no additional revenue impact from new government price-setting or its Medicaid agreement, there is no reason to raise the current assessment of this risk.

The disconnect between GAAP profit and operating performance makes reported earnings far more volatile than the business itself. Skyrizi-related contingent consideration is remeasured on expected sales, so the better Skyrizi performs, the higher the GAAP charge, and IPR&D is expensed in full in the quarter a deal is signed; in 2025, a $6.5 billion contingent consideration change and $5.016 billion of IPR&D left GAAP diluted EPS at only $2.36[17]. In the second quarter of 2026, the contingent consideration charge was $1.5 billion[21], and GAAP EPS was $2.03 against adjusted EPS of $3.65. If contingent consideration and IPR&D together fall back within $2 billion in the third quarter and the gap between GAAP and adjusted EPS narrows, this risk's distortion of reported results would ease.

Competitive and safety risk points directly at the company's most concentrated revenue source. New oral IL-23, IL-17 and other competitors are competing for new psoriasis and inflammatory bowel disease patients, and the JAK class that includes Rinvoq carries boxed warnings for serious infections, malignancy and thrombosis; management acknowledges that new launches in core areas could affect Skyrizi's share gains but says it has not observed a material impact so far[37]. Skyrizi and Rinvoq generated about $8.03 billion together in the second quarter, about 47% of total revenue, and each percentage point of lost Skyrizi growth corresponds to roughly $55 million of quarterly revenue. If Skyrizi reaches at least $5.8 billion in the third quarter, Rinvoq growth is at least 22% and management reaffirms that new competitors have had no material impact, this risk has not materialized.

Persistent weakness in aesthetics demand would drag on high-margin revenue. Aesthetics is consumer-paid and exposed to discretionary spending and competitors, and in 2025 U.S. Botox Cosmetic fell 11% because of unfavorable pricing from loyalty program changes, lower market share and weaker consumer demand[41]. Second-quarter aesthetics revenue was $1.282 billion, so every 5 percentage points of decline removes about $64 million of quarterly revenue, and aesthetics carries a higher gross margin than the company average. If third-quarter aesthetics growth returns above 0% operationally and U.S. Botox Cosmetic turns positive, this risk would ease noticeably.

Acquisition and leverage risk comes from the all-cash Apogee deal alongside a large, continuing dividend. AbbVie paid about $10.9 billion in cash for Apogee, issued $10 billion of notes in August and targets a net leverage ratio of 2x within two to three years of closing[3], while paying $6.2 billion of dividends in the first half, or about $3.1 billion per quarter[22]. At the end of June, total debt was about $70.8 billion and cash was $6.569 billion[23]; the new notes add several hundred million dollars of annualized interest, and Apogee will dilute EPS by about $0.46 in 2027[11]. If third-quarter net interest stays at or below about $800 million and the company reaffirms its 2x net leverage target without another large debt-funded acquisition, this risk remains contained.

What to Watch Next

• Immunology handoff: Skyrizi revenue was $5.505 billion in the second quarter of 2026; at least about $5.8 billion in the third quarter would confirm the pace, while less than $5.6 billion with a cut to the full-year assumption would falsify it.
• Immunology handoff: Rinvoq grew 23.7% operationally in the second quarter; growth of at least 22% would confirm momentum, while a clear slowdown alongside competitor share gains would falsify it. Humira's decline of 36.1% should stay within -30% to -40%.
• Neuroscience ramp: second-quarter revenue was $3.228 billion; the third quarter needs at least about $3.3 billion, and less than $3.15 billion with a cut to the full-year assumption would falsify the ramp. Watch whether Vraylar (18.9% in the second quarter) stays above 15% and whether Vyalev ($256 million) reaches about $290 million, since a sequential Vyalev decline would falsify the view.
• Aesthetics stabilization: operational growth was -0.9% in the second quarter; a return above 0% would confirm stabilization, while two consecutive declines worse than -3% would falsify it. U.S. Botox Cosmetic (-2.4%) should turn positive and Juvederm (-6.6%) should narrow to within -5%.
• EPS after Apogee: adjusted EPS was $3.65 in the second quarter against third-quarter guidance of $3.84-$3.88; at least $3.86 excluding third-quarter IPR&D would confirm conversion, while less than $3.84 or a cut to full-year guidance would falsify it. An adjusted operating margin below 47% (48.3% in the second quarter) combined with net interest above about $800 million ($679 million in the second quarter) would weaken the case.

Conclusion

AbbVie's business is driven by two newer immunology drugs and constrained by the U.S. pricing environment; its current financial position combines a return to double-digit revenue growth and very high adjusted margins with a balance sheet that Apogee has re-levered. Second-quarter revenue was $16.990 billion, up 10.2%, adjusted EPS was $3.65, and Skyrizi and Rinvoq together generated about $8 billion in the quarter, enough to fill the gap left by Humira[2]; at the same time, debt stood at about $70.8 billion at the end of June, and another $10 billion of notes followed in August. The central unresolved relationship is whether Skyrizi and neuroscience growth can cover Apogee's added R&D and interest costs while their growth rates naturally slow and aesthetics stays weak, and still bring third-quarter adjusted EPS inside the $3.84-$3.88 guidance.

Few independent interpretations have been published since the second-quarter results. In an August 17, 2026 article, Jack Green of Openbook Analytics argued that AbbVie has cleared its biggest hurdle: Humira fell 36.1% to $756 million in the second quarter, yet total revenue still grew 10.2% because Skyrizi and Rinvoq's roughly $8 billion in quarterly revenue has filled the gap; he also noted that the two drugs generate close to half of company revenue, so any safety signal, reimbursement setback or competitive trial result would matter disproportionately, and he listed consumer-funded Botox Cosmetic and Juvederm, which have been close to flat, as a possible drag on group growth[42]. His view matches the optimistic direction of the first core debate, but the concentration risk he stresses is exactly that debate's falsifier, and his aesthetics judgment matches the evidence against stabilization in the third debate. Between the second-quarter report and the end of September, other coverage consisted mostly of results recaps or share-price moves, and no other independent argument was included, so the neuroscience ramp and the post-Apogee EPS conversion currently lack an outside independent reading to compare against.

The combination that would most strengthen the current understanding is third-quarter Skyrizi revenue of at least about $5.8 billion, neuroscience revenue of at least about $3.3 billion, a return to positive operational growth in aesthetics, adjusted EPS excluding IPR&D of at least $3.86 and net interest held within about $790 million. Conversely, if Skyrizi falls below $5.6 billion and the full-year assumption is cut, aesthetics declines for a second consecutive quarter by more than 3%, or EPS excluding IPR&D comes in below $3.84, the immunology handoff or the post-Apogee profit conversion would be weaker than the current understanding.

Sources

[1] Drillr earnings calendar (updated 2026-09-29) · ABBV 2026-10-30 call · 2026-09-29 · Drillr earnings calendar · https://gateway.drillr.ai/mcp/private

[2] ABBV 8-K filed 2026-07-31 · Q2 2026 results highlights · 2026-07-31 · 8-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm

[3] ABBV Q2 2026 earnings call 2026-07-31 · 2026 and Q3 guidance · 2026-07-31 · earnings-call · https://gateway.drillr.ai/mcp/private

[4] ABBV 8-K filed 2026-09-03 · Apogee closing and Q3 EPS guidance · 2026-09-03 · 8-K · https://www.sec.gov/Archives/edgar/data/1551152/000110465926104940/tm2624674d1_ex99-1.htm

[5] Drillr analyst_financial_estimates (updated 2026-09-29) · ABBV quarter ending 2026-09-30 · 2026-09-29 · Drillr analyst_financial_estimates · https://gateway.drillr.ai/mcp/private

[6] ABBV 8-K filed 2026-07-31 · six-month 2026 key product revenues · 2026-07-31 · 8-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm

[7] ABBV 8-K filed 2026-07-31 · Q2 2026 key product revenues · 2026-07-31 · 8-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm

[8] ABBV 10-K filed 2026-02-20 · product revenue drivers FY2025 · 2026-02-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm

[9] ABBV 10-Q filed 2026-08-03 · IRA Botox selection and US investment · 2026-08-03 · 10-Q · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm

[10] ABBV 8-K filed 2026-07-31 · Q2 2026 recent events · 2026-07-31 · 8-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm

[11] ABBV 8-K filed 2026-09-03 · Apogee EPS dilution · 2026-09-03 · 8-K · https://www.sec.gov/Archives/edgar/data/1551152/000110465926104940/tm2624674d1_ex99-1.htm

[12] ABBV 10-K filed 2026-02-20 · distribution and wholesalers · 2026-02-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm

[13] ABBV 8-K filed 2026-07-31 · Q2 2026 margins and EPS · 2026-07-31 · 8-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm

[14] ABBV 10-K filed 2026-02-20 · net revenues by geography FY2023-FY2025 · 2026-02-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm

[15] ABBV 10-K filed 2026-02-20 · immunology net revenues FY2023-FY2025 · 2026-02-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm

[16] ABBV 10-K filed 2026-02-20 · 2025 financial results summary · 2026-02-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm

[17] ABBV 10-K filed 2026-02-20 · acquired IPR&D and contingent consideration FY2025 · 2026-02-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm

[18] ABBV 10-K filed 2026-02-20 · gross margin and operating costs FY2025 · 2026-02-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm

[19] ABBV 10-K filed 2026-02-20 · cash flows FY2025 · 2026-02-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm

[20] ABBV 8-K filed 2026-07-31 · Q2 2026 statement of earnings · 2026-07-31 · 8-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm

[21] ABBV 10-Q filed 2026-08-03 · Q2 2026 contingent consideration and interest · 2026-08-03 · 10-Q · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm

[22] ABBV 10-Q filed 2026-08-03 · H1 2026 cash flows, dividends and buybacks · 2026-08-03 · 10-Q · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm

[23] ABBV 10-Q filed 2026-08-03 · balance sheet June 30 2026 · 2026-08-03 · 10-Q · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm

[24] ABBV 8-K filed 2026-08-18 · August 2026 notes offering · 2026-08-18 · 8-K · https://www.sec.gov/Archives/edgar/data/1551152/000110465926098367/tm2623337d1_8k.htm

[25] ABBV 8-K filed 2026-07-31 · full-year 2026 outlook · 2026-07-31 · 8-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm

[26] ABBV 10-Q filed 2026-08-03 · Q2 2026 debt and Apogee financing · 2026-08-03 · 10-Q · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm

[27] ABBV 10-K filed 2026-02-20 · competition and biosimilars · 2026-02-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm

[28] ABBV Q2 2026 earnings call 2026-07-31 · commercial and pipeline highlights · 2026-07-31 · earnings-call · https://gateway.drillr.ai/mcp/private

[29] ABBV 10-K filed 2026-02-20 · Rinvoq exclusivity settlement · 2026-02-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm

[30] ABBV 8-K filed 2026-07-31 · Boey and Skinvive approvals · 2026-07-31 · 8-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm

[31] ABBV Q1 2026 earnings call 2026-04-29 · TrenibotE CRL · 2026-04-29 · earnings-call · https://gateway.drillr.ai/mcp/private

[32] ABBV 10-K filed 2026-02-20 · IRA price-setting and US pricing agreement · 2026-02-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm

[33] ABBV Q2 2026 earnings call 2026-07-31 · psoriasis competition and tavapadon Q&A · 2026-07-31 · earnings-call · https://gateway.drillr.ai/mcp/private

[34] ABBV Q2 2026 earnings call 2026-07-31 · segment performance · 2026-07-31 · earnings-call · https://gateway.drillr.ai/mcp/private

[35] ABBV 10-K filed 2026-02-20 · neuroscience net revenues FY2023-FY2025 · 2026-02-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm

[36] ABBV 10-Q filed 2026-08-03 · Q2 2026 product revenue drivers · 2026-08-03 · 10-Q · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm

[37] ABBV Q2 2026 earnings call 2026-07-31 · stated risks · 2026-07-31 · earnings-call · https://gateway.drillr.ai/mcp/private

[38] ABBV 10-K filed 2026-02-20 · aesthetics net revenues FY2023-FY2025 · 2026-02-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm

[39] ABBV 10-Q filed 2026-08-03 · Q2 2026 aesthetics revenue drivers · 2026-08-03 · 10-Q · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm

[40] ABBV 8-K filed 2026-07-06 · Q2 2026 acquired IPR&D update · 2026-07-06 · 8-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000021/abbv-20260630nonxgaapxex991.htm

[41] ABBV 10-K filed 2026-02-20 · aesthetics revenue drivers FY2025 · 2026-02-20 · 10-K · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm

[42] Openbook Analytics 2026-08-17 · Inside AbbVie (ABBV) Shares: Immunology, Neuroscience and Botox · 2026-08-17 · Openbook Analytics · https://www.openbookanalytics.com/news/insights/inside-abbvie-abbv-shares-immunology-neuroscience-and-botox